http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 06:50:55 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Pharvaris+publishes+review+on+bradykinin+B2+receptor+as+therapy+target/26797913.html <p>Pharvaris (Nasdaq: PHVS), a biopharmaceutical company based in Zug, Switzerland, announced the publication of a review article in <em>Clinical Reviews in Allergy & Immunology</em> examining the role of the bradykinin B2 receptor in bradykinin-mediated angioedema and related conditions.</p><p>The article summarizes decades of scientific and clinical research on bradykinin B2 receptor antagonism as a therapeutic approach for conditions including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). It also reviews evidence suggesting bradykinin signaling may play a role in broader immunological and inflammatory disorders such as bronchial asthma, chronic cough, allergic rhinitis, and chronic urticaria.</p><p>Anne Lesage, Ph.D., http://www.streetinsider.com/Corporate+News/Pharvaris+publishes+review+on+bradykinin+B2+receptor+as+therapy+target/26797913.html Wed, 22 Jul 2026 06:50:55 -0400 PHVS http://www.streetinsider.com/FDA/Pharvaris+publishes+review+on+bradykinin+B2+receptor+as+therapy+target/26797913.html <p>Pharvaris (Nasdaq: PHVS), a biopharmaceutical company based in Zug, Switzerland, announced the publication of a review article in <em>Clinical Reviews in Allergy & Immunology</em> examining the role of the bradykinin B2 receptor in bradykinin-mediated angioedema and related conditions.</p><p>The article summarizes decades of scientific and clinical research on bradykinin B2 receptor antagonism as a therapeutic approach for conditions including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). It also reviews evidence suggesting bradykinin signaling may play a role in broader immunological and inflammatory disorders such as bronchial asthma, chronic cough, allergic rhinitis, and chronic urticaria.</p><p>Anne Lesage, Ph.D., http://www.streetinsider.com/FDA/Pharvaris+publishes+review+on+bradykinin+B2+receptor+as+therapy+target/26797913.html Wed, 22 Jul 2026 06:50:55 -0400 PHVS http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797907.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive review http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797907.html Wed, 22 Jul 2026 06:50:00 -0400 PHVS http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797907.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive review http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797907.html Wed, 22 Jul 2026 06:50:00 -0400 PHVS http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Press+Releases/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html <ul type="disc"><li>Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema</li><li>Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases</li></ul> <p>ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PLguNBWy2yylu6W9wP90BQxwNTAZljB1gK76v4_HIlQCMx_8Qf9sBC18z_d8kv8-QEX-9Jhw0Jh6Kml7WXB_oQ==" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive http://www.streetinsider.com/Globe+Newswire/Publication+in+Clinical+Reviews+in+Allergy+%26amp%3B+Immunology+Summarizes+Decades+of+Evidence+Supporting+Bradykinin+B2+Receptor+as+a+Validated+Therapeutic+Target+in+Bradykinin-Mediated+Angioedema/26797909.html Wed, 22 Jul 2026 06:50:00 -0400 A.37612190 O.25604838 O.29407519 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+13++Filed+by%3A+Modig+Berndt/26773342.html si-local-file:///var/storage/secattach/20260715/26773342.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+13++Filed+by%3A+Modig+Berndt/26773342.html Wed, 15 Jul 2026 13:08:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+13++Filed+by%3A+Modig+Berndt/26773342.html si-local-file:///var/storage/secattach/20260715/26773342.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+13++Filed+by%3A+Modig+Berndt/26773342.html Wed, 15 Jul 2026 13:08:00 -0400 O.25604838 PHVS http://www.streetinsider.com/New+Coverage/Wells+Fargo+Starts+Pharvaris+B.V.+%28PHVS%29+at+Overweight/26769900.html <p>Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Overweight rating and a price target of $55.00.</p><p>The analyst comments: “We highlight key differentiations of deucrictibant, an oral HAE therapy w/ injectable drug-like efficacy, representing a compelling new option both as an on-demand therapy and in the prophylaxis setting. In addition, the bradykinin B2 receptor-targeted MOA acts at the key signaling bottleneck and may confer broadest coverage of bradykinin mediated angioedemas. We see $1.8B peak sales potential across deucrictibant indications.</p><p>PHVS's deucrictibant demonstrated strong efficacy as on-demand therapy (ODT) in phase 3, with faster timeto-onset of symptom http://www.streetinsider.com/New+Coverage/Wells+Fargo+Starts+Pharvaris+B.V.+%28PHVS%29+at+Overweight/26769900.html Wed, 15 Jul 2026 05:11:37 -0400 PHVS http://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Starts+Pharvaris+B.V.+%28PHVS%29+at+Overweight/26769900.html <p>Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Overweight rating and a price target of $55.00.</p><p>The analyst comments: “We highlight key differentiations of deucrictibant, an oral HAE therapy w/ injectable drug-like efficacy, representing a compelling new option both as an on-demand therapy and in the prophylaxis setting. In addition, the bradykinin B2 receptor-targeted MOA acts at the key signaling bottleneck and may confer broadest coverage of bradykinin mediated angioedemas. We see $1.8B peak sales potential across deucrictibant indications.</p><p>PHVS's deucrictibant demonstrated strong efficacy as on-demand therapy (ODT) in phase 3, with faster timeto-onset of symptom http://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Starts+Pharvaris+B.V.+%28PHVS%29+at+Overweight/26769900.html Wed, 15 Jul 2026 05:11:37 -0400 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+11++Filed+by%3A+Lu+Peng/26768032.html si-local-file:///var/storage/secattach/20260714/26768032.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+11++Filed+by%3A+Lu+Peng/26768032.html Tue, 14 Jul 2026 15:46:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+11++Filed+by%3A+Lu+Peng/26768032.html si-local-file:///var/storage/secattach/20260714/26768032.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jul+11++Filed+by%3A+Lu+Peng/26768032.html Tue, 14 Jul 2026 15:46:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Modig+Berndt/26762945.html si-local-file:///var/storage/secattach/20260713/26762945.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Modig+Berndt/26762945.html Mon, 13 Jul 2026 16:39:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Modig+Berndt/26762945.html si-local-file:///var/storage/secattach/20260713/26762945.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Modig+Berndt/26762945.html Mon, 13 Jul 2026 16:39:00 -0400 O.25604838 PHVS http://www.streetinsider.com/FDA/FDA+accepts+Pharvaris+NDA+for+oral+HAE+attack+treatment+deucrictibant/26732482.html <p>Pharvaris (Nasdaq: PHVS) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of hereditary angioedema attacks, according to a company statement.</p> <p>The FDA has set a PDUFA target action date of April 23, 2027.</p> <p>Deucrictibant is an oral bradykinin B2 receptor antagonist. The company claims it would be the first oral therapy of its type approved to treat HAE attacks, if the NDA is approved.</p> <p>The NDA draws on clinical data covering treatment of more than 1,300 HAE attacks. The pivotal Phase 3 study, RAPIDe-3, enrolled participants aged http://www.streetinsider.com/FDA/FDA+accepts+Pharvaris+NDA+for+oral+HAE+attack+treatment+deucrictibant/26732482.html Mon, 06 Jul 2026 06:50:14 -0400 PHVS http://www.streetinsider.com/Press+Releases/Pharvaris+Announces+FDA+Acceptance+of+New+Drug+Application+for+Deucrictibant+IR+for+On-Demand+Treatment+of+Hereditary+Angioedema+Attacks/26732479.html <ul type="disc"><li>If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks</li><li>NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile</li><li>PDUFA action date set for April 23, 2027<br /><br /></li></ul> <p>ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6CpSfpCo16MJBUuFa7R2rRlFfTy3AThnKyHGAkHYnBUkPYsW8seqrhoQOhR2V96XsXuLcNpkJVqWHXec1vfyuLKLnGQwb1u7aJfPbnu_oQ62J6bRRcDzx_mkZwgu7V84XtEleHg_KcrTk0PTGOYXgyrixafNaCfGFYOvloIFHPu2IiA_ctQryDxJZfT1fIpYrqKaN7nhBzBJz6QXEgHhRu_o-toMYcXUVl0YsgNQMIA=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 http://www.streetinsider.com/Press+Releases/Pharvaris+Announces+FDA+Acceptance+of+New+Drug+Application+for+Deucrictibant+IR+for+On-Demand+Treatment+of+Hereditary+Angioedema+Attacks/26732479.html Mon, 06 Jul 2026 06:50:00 -0400 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+Announces+FDA+Acceptance+of+New+Drug+Application+for+Deucrictibant+IR+for+On-Demand+Treatment+of+Hereditary+Angioedema+Attacks/26732479.html <ul type="disc"><li>If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks</li><li>NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile</li><li>PDUFA action date set for April 23, 2027<br /><br /></li></ul> <p>ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6CpSfpCo16MJBUuFa7R2rRlFfTy3AThnKyHGAkHYnBUkPYsW8seqrhoQOhR2V96XsXuLcNpkJVqWHXec1vfyuLKLnGQwb1u7aJfPbnu_oQ62J6bRRcDzx_mkZwgu7V84XtEleHg_KcrTk0PTGOYXgyrixafNaCfGFYOvloIFHPu2IiA_ctQryDxJZfT1fIpYrqKaN7nhBzBJz6QXEgHhRu_o-toMYcXUVl0YsgNQMIA=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 http://www.streetinsider.com/Globe+Newswire/Pharvaris+Announces+FDA+Acceptance+of+New+Drug+Application+for+Deucrictibant+IR+for+On-Demand+Treatment+of+Hereditary+Angioedema+Attacks/26732479.html Mon, 06 Jul 2026 06:50:00 -0400 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jun+29++Filed+by%3A+Schikan+Johannes+Gerardus+Christiaan+Petrus/26722521.html si-local-file:///var/storage/secattach/20260701/26722521.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jun+29++Filed+by%3A+Schikan+Johannes+Gerardus+Christiaan+Petrus/26722521.html Wed, 01 Jul 2026 19:06:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jun+29++Filed+by%3A+Schikan+Johannes+Gerardus+Christiaan+Petrus/26722521.html si-local-file:///var/storage/secattach/20260701/26722521.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+Jun+29++Filed+by%3A+Schikan+Johannes+Gerardus+Christiaan+Petrus/26722521.html Wed, 01 Jul 2026 19:06:00 -0400 O.25604838 PHVS